AdKCNH2-G628S

AdKCNH2-G628S is an investigational gene therapy designed to prevent atrial fibrillation, particularly post-operative atrial fibrillation (POAF). It utilizes an adenoviral vector to deliver a dominant-negative mutant of the KCNH2 gene (G628S) specifically to cardiac atrial tissue. The KCNH2 gene encodes the hERG potassium channel subunit Kv11.1, which is critical for cardiac myocyte repolarization. The G628S mutation acts as a dominant negative, effectively eliminating the function of this potassium channel in targeted cells and thereby prolonging atrial action potential duration. This selective molecular blockade disrupts reentrant electrical circuits that maintain AF without affecting ventricular electrophysiology, offering a potentially safer alternative to systemic antiarrhythmic drugs[1][3][4][5]. Preclinical studies in animal models have demonstrated efficacy in reducing AF incidence and maintaining sinus rhythm with no significant adverse effects or off-target toxicity[6][8]. Clinical development reached Phase 1 for POAF but has since been suspended/discontinued[2].

Other names

KCNH2-G628S gene therapyKCNH-2-G628S gene therapyKCNH 2-G628S gene therapyAdenovirus-KCNH2-G628SAdenovirus-KCNH-2-G628SAdenovirus-KCNH 2-G628S